Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies

Background: M5A is a humanized monoclonal antibody (mAb) directed against carcinoembryonic antigen (CEA) The purpose of this first in human phase I dose-escalation trial was to characterize the toxicities and determine the maximum tolerated dose (MTD) of yttrium-90 ((90)Y)-DOTA-M5A as a single agent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biother Radiopharm
Main Authors: Akhavan, David, Yazaki, Paul, Yamauchi, Dave, Simpson, Jennifer, Frankel, Paul H., Bading, James, Colcher, David, Poku, Kofi, Chen, Yi-jen, Lim, Dean, Cristea, Mihaela, Wu, Anna, Shively, John, Wong, Jeffrey Y.C.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044770/
https://ncbi.nlm.nih.gov/pubmed/31910346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2019.2992
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados